Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) FCF Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed FCF Margin for 16 consecutive years, with 4.26% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 1210.0% to 4.26% in Q3 2025 year-over-year; TTM through Sep 2025 was 8.52%, a 765.0% increase, with the full-year FY2024 number at 1.28%, down 1218.0% from a year prior.
  • FCF Margin was 4.26% for Q3 2025 at Harvard Bioscience, down from 13.04% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 16.34% in Q3 2023 to a low of 8.54% in Q1 2022.
  • A 5-year average of 3.49% and a median of 3.28% in 2021 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -2418bps in 2024, then soared 2024bps in 2025.
  • Harvard Bioscience's FCF Margin stood at 0.73% in 2021, then skyrocketed by 1279bps to 8.6% in 2022, then skyrocketed by 43bps to 12.34% in 2023, then plummeted by -53bps to 5.8% in 2024, then fell by -27bps to 4.26% in 2025.
  • Per Business Quant, the three most recent readings for HBIO's FCF Margin are 4.26% (Q3 2025), 13.04% (Q2 2025), and 11.36% (Q1 2025).